Management of hemostasis in a patient with liver cirrhosis in the perioperative period: 616.36-004:616.151.5

Abstract

Summary. Patients with liver cirrhosis are characterized by significant hemostasis changes. A clinical case is described of patient management with liver cirrhosis, portal hypertension, stomach varicose veins, operated at the height of gastrointestinal bleeding, with revealed thromboembolic complications (pulmonary embolism and deep vein thrombosis of the lower legs). Cava filter was installed in preoperative period. In the first 2 days of the postoperative period, antithrombin III (AT-III) concentrate was adminis- tered as an anticoagulant, 1000 units each due to its initial deficiency (64%) and to further ensure the therapy efficacy with low molecular weight heparins (LMWH). By increasing the platelet count from 66 × 109/L to 200 × 109/L, a therapeutic dose of parnaparin sodium was prescribed as an anticoagulant. The efficacy of LMWH therapy was assessed by thromboelastography (TEG). On the day 9 after surgery heparin resistance was diagnosed with thrombocytosis (more than 1 million), hyperfibrinogenemia, high activity of VIII factor and re-identified AT-III deficiency (53%). Clinically, heparin resistance was manifested by floating thrombus in the right femoral vein. The antiaggregant clopidogrel (75 mg) was added to the maximum therapeutic dose of parnaparin (17,000 anti-Xa), and the administration of AT-III concentrate (1000 IU) was started for 3 days. Heparin resistance was overcome with normaliza- tion of AT-III level (89%), platelet disaggregation was achieved. Complete lysis of floating thrombus in the right femoral vein was diagnosed after 7 days. Later the patient was treated with parnaparin (17,000 anti-Xa activity per day) and clopidogrel (75 mg/day) during 1 month outpatiently. According to computer pulmonary angiography, complete thrombus lysis in the pulmonary artery was revealed, the cava filter was removed. Conclusions. Hemostasis monitoring in patient with liver cirrhosis made it possible to control the adequacy of the anticoagulant therapy and to use the arsenal of drugs available to the clinician.

References:

1. Lisman T., Porte R. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878– DOI: 10.1182/blood‐2010–02–261891. 

2. Mucino‐Bermejo J., Carrillo‐Esper R., Uribe M., Mendez‐Sanchez Coagulation abnormalities in the cirrhotic. Ann Hepatol. 2013;12(5):713–24. 

3. Northup P. A history of coagulopathy in liver disease: legends and myths. Clin Liver Dis (Hoboken). 2020;16(Suppl 1):56–72. DOI: 10.1002/cld.954. 

4. Mannucci P., Canciani M., Forza I. et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98(9):2730–5. DOI: 10.1182/blood.v98.9.2730. 

5. Dong J., Moake J., Nolasco L. et al. ADAMTS‐13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100(12):4033–9. DOI: 10.1182/blood‐2002–05–1401. 

6. Licinio R., Principi M., Losurdo G. at al. Low molecular weight heparin in portal vein thrombosis of cirrhotic patients: only thera‐ peutic purposes? Scientific World Journal. 2014;2014:895839. DOI: 1155/2014/895839. 

7. Pietry L., Montalti R., Nicolini D. at al. Perioperative thrombo‐ prophylaxis in liver transplant patients. World J Gastroenterol. 2018;24(27):2931–48. DOI: 10.3748/wjg.v24.i27.2931. 

8. Kitsenko E.A., Anisimov A. Yu., Andreev A.I. The modern state of bleeding from variceal veins of esophagus and stomach. Vest- nik sovremennoj klinicheskoj mediciny. 2014;7(5):89–98. (In Russ.). 
 
9. Imura S., Shimada M., Utsunomya T. at al. Impact of splenec‐ tomy in patients with liver cirrhosis: results from 18 patients in a single center experience. Hepatol Res. 2010;40(9):894–900. DOI: 1111/j.1872–034X.2010.00688.x. 

10. Ikegami T., Shimada M., Imura S. Recent role of splenectomy in chronic hepatic disorders. Hepatol Res. 2008;38(12):1159–71. DOI: 10.1111/j.1872–034X.2008.00384.x. 

11. Hartmann M., Szalai C., Saner F. Hemostasis in liver transplanta‐ tion: pathophysiology, monitoring, and treatment. World J Gastro- enterol. 2016;22(4):1541–50. DOI: 10.3748/wjg.v22.i4.1541.
12. Labidi A., Baccouche H., Fekih M. at al. The relationship between coagulation disorders and the risk of bleeding in cirrhotic patients. Ann Hepatol. 2019;18(4):627–32. DOI: 10.1016/j.aohep.2018.12.007.
13. Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18(2):281–91. DOI: 10.1016/j.cld.2013.12.001.
14. Kawanaka H., Akahoshi T., Itoh S. at al. Optimizing risk stratifi‐ cation in portal vein thrombosis after splenectomy and its pri‐ mary prophylaxis with antithrombin III concentrates and dana‐ poroid sodium in liver cirrhosis with portal hypertension. J Am Coll Surg. 2014;5:865–74. DOI: 10.1016/j.jamcollsurg.2014.07.939.
15. Prasolov N. V., Vodolazskaya T. V., Shekina A. E., Ovchin‐ nikov N.V. The effectiveness of parnaparin in the prevention of venous thromboembolic complications in the postopera‐ tive period. Gematologiya i transfuziologiya. 2020;65(S1):208–9. (In Russ.).
16. Camporese G., Bernardi E., Noventa F. Update on clinical use of the low‐molecular‐weight heparin, parnaparin. Vasc Health Risk Manag.2009;5:819–31. DOI: 10.2147/vhrm.s3430.
17. Imberti D., Baldini Е., Pierfranceschi M.G. еt al. Prophylaxis of venous thromboembolism with low molecular weight hepa‐ rin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Оbes Surg. 2014;24(2):284–91. DOI: 10.1007/s11695–013–1105‐
18. Bulanov A. Yu., Prasolov N.V., Shulutko E.M. The problem of hepa‐ rin resistance in clinical practice. Tol’yattinskij medicinskij konsil- ium. 2014;(3–4):21–4. (In Russ.).